Agreement - February 20, 2023
Aqilion enters licensing and research collaboration with Merck
Aqilion has announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. “We are delighted and proud to announce this collaboration with Merck as it validates our business strategy of generating highly innovative discovery projects in combination with […]
Biotech Business - February 7, 2023
TILT Biotherapeutics closes 22 million EUR financing round
The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. This follows on from the first close of 10 million EUR in June 2022. This final close of 12 million EUR includes 5.9 million EUR equity from the European Innovation Council (EIC) Fund as well as a 2.1 […]
Biotech Business - January 30, 2023
AdjuTec Pharma attracts public funding to optimize manufacturing
Just before Christmas, the Norwegian company announced that it has received support from Oslo County of 1.950 million NOK. The funding will support optimization of the synthesis of our two lead compounds, APC148 and APC247. The program will define the optimal characteristics of the substances that will be used for microbiology testing as well as […]
Biotech Business - January 20, 2023
Evaxion receives FDA fast-track designation
The U.S. Food and Drug Administration has granted the designation for the company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA. In December 2022, Evaxion received FDA approval to proceed with its Phase 2b clinical trial, where EVX-01 is given in combination with KEYTRUDA to patients with metastatic melanoma. On January 17, 2023, Evaxion furthermore […]
Biotech Business - January 18, 2023
AlzeCure selects candidate drug and enters next phase with Alzstatin
AlzeCure Pharma has chosen a candidate drug (CD) and started the preclinical development phase with the company’s preventive and disease-modifying candidate drug Alzstatin ACD680. ACD680 is being developed within AlzeCure’s Alzstatin platform, with the aim of developing a preventive and disease-modifying drug for the early treatment of Alzheimer’s disease. In the project, a CD has […]
Agreement - January 17, 2023
Bristol Myers Squibb and Karolinska University Hospital enter collaboration
Karolinska University Hospital’s cancer department has signed an agreement with Bristol Myers Squibb to start an oncology and hematology research collaboration focusing on advancing research and generating data with an aim to deliver innovative therapies for patients. The organizations will centralize the work through a steering committee consisting of experts from both organizations to discuss […]
